 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...1011121314151617181920...3839» |
- || Review, Journal: Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. (Pubmed Central) - Oct 10, 2021
Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP...Further research into agents acting on the IL-36 pathway and other targeted therapies has the potential to transform the future treatment of patients with pustular psoriasis. This article reviews the clinical features of PPP and GPP, and current understanding of the genetics and immunopathology of these conditions; it also provides an update on emerging treatments.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Planifier une grossesse chez une patiente avec un psoriasis. (Pubmed Central) - Oct 9, 2021
In a patient who is planning to become pregnant, the treatments to be favored will be according to the severity of the psoriasis: topical steroids, UVB, cyclosporine, anti TNFα, notably certolizumab pegol. In a patient who is planning to become pregnant and has already been treated for psoriasis, consideration should be given to the recommended delay between stopping treatment and conception.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse. (Pubmed Central) - Oct 9, 2021
Acitretin and methotrexate are contraindicated...Overall, it is recommended that biologic agents should not be continued beyond the second trimester because of the risk of maternal-fetal infection. If a biologic agent should be initiated during pregnancy, tanercept or certolizumab will be preferred, because of their low transplacental passage and more extensive safety data.
- || Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients. (Pubmed Central) - Oct 2, 2021
Disease activity, CATHK, RANKL and VITD may be associated with the effects of anti-TNF treatment on QCT BMD changes. RA and AS may differ in this respect.
- || Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis. (Pubmed Central) - Oct 1, 2021
DMARD treatment, contrary to general belief, seemed to have no harmful effect on fertility, possibly because it resulted in better controlled disease activity. More research is needed to improve guidance for patients with RA with a child wish.
- | New P4 trial: Remission after suspension of TNF alpha therapies in RA Remissione dopo terapia con farmaci Anti TNF in pazienti affetti da Artrite Reumatoide (EUDRACT) - Sep 30, 2021
P4, N=60, Ongoing, Sponsor: AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Certolizumab pegol 3-year durability of efficacy for moderate to severe plaque psoriasis in different subgroups: CIMPASI-1 and CIMPASI-2 () - Sep 24, 2021 - Abstract #EADV2021EADV_2757;
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Efficacy of certolizumab pegol for psoriasis of the head and neck over three years of treatment in two phase 3 trials: CIMPASI-1 and CIMPASI-2 () - Sep 24, 2021 - Abstract #EADV2021EADV_2745;
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Efficacy of certolizumab pegol in psoriasis patients failing to respond to etanercept: Three-Year results from the randomised phase 3 CIMPACT trial () - Sep 24, 2021 - Abstract #EADV2021EADV_2690;
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Pharmacovigilance Data on Pregnancy Outcomes in Women with Psoriatic Disease Exposed to Certolizumab Pegol () - Sep 24, 2021 - Abstract #EADV2021EADV_1723;
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report. (Pubmed Central) - Sep 22, 2021
TNF inhibitors should be discontinued in patients who develop rapidly progressive glomerulonephritis, and these patients should be treated with immunosuppressive drugs, such as massive corticosteroids and cyclophosphamide. In the present case, rituximab was useful for not only the treatment, but also for the preservation of fertility.
- || Clinical, Journal, Real-world evidence: Pattern of drug use in patients with psoriatic arthritis in Italy: study in a real-world setting. (Pubmed Central) - Sep 22, 2021
This analysis provided insights on drug utilization patterns for PsA in an Italian real-world setting. Our results show that treatment regimen changes occur in a high proportion of PsA patients.
- [VIRTUAL] Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_2068;
Mixed treatment comparisons showed no statistically significant differences with upadacitinib (OR 0.12; 95% CI 0.01-2.66), guselkumab (OR 0.33; 95% CI 0.02-4.68,) methotrexate-etanercept (OR 0.49; 95% CI 0.04-5.49), golimumab (OR 0.50; 95% CI 0.04-5.50), etanercept (OR 0.50; 95% CI 0.04-5.53), apremilast (OR 0.74; 95% CI 0.12-4.49), adalimumab (OR 1.39, 95% CI 0.26-7.44), certolizumab (OR 1.50; 95% CI 0.06-37.13), and secukinumab (OR 2.85 95% CI 0.58-14.48) when compared to placebo. During limited follow-up period in controlled clinical trials, composite MACE outcomes were not different among PsA patients treated with biologics and targeted synthetic disease modifying antirheumatic agents.
- [VIRTUAL] Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_2065;
Secondary failure was the most prevalent reason for discontinuation, suggesting that further research should be conducted to examine reasons for loss of efficacy and immunogenicity of TNF-α inhibitors. Table 1: Characteristics of TNF-α Inhibitor Discontinuation
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_2060;
P3
At baseline, 60.8% of pts were employed outside the home. Through Week 216, fewer days of paid work absence (absenteeism) were reported by pts achieving ACR70 (4.1 [95% confidence interval: 0.4, 7.9]), DAPSA REM (3.3 [1.1, 5.5]) and the intermediate measures, than ACR20 non-responders (35.7 [17.9, 53.5]) and those with DAPSA HDA (54.0 [21.5, 86.5]; Figure 1A , B ).
- [VIRTUAL] Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_2051;
This analysis highlights the heterogeneity in presentation of PsA domains. In this real-world population, improvement was seen across all PsA domains after initiation of TNFi treatment.
- [VIRTUAL] Disease Activity and Outcome in Pregnancies of Patients with SpA - Data from the German Pregnancy Register RHEKISS () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1940;
SpA patients treated with bDMARDs at conception are not at higher risk for adverse pregnancy outcomes compared to those without bDMARD exposure. Furthermore, our results confirmed the findings of smaller studies that discontinuation of bDMARDs after conception is associated with increased disease activity during pregnancy and after birth and a higher risk of flares.
- [VIRTUAL] Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1629;
Abatacept may have a lower risk of RTIs when used for treatment of PsA. Further analyses are warranted to assess the severity and type of RTIs associated with these treatments.
- [VIRTUAL] Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1625;
We have demonstrated superiority of TNFi versus secukinumab in regards to active entheseal disease. The SPARCC score correlated with baseline active entheseal US disease and with change in response to treatment highlighting it ability to capture active entheseal disease.
- [VIRTUAL] Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1519;
Plasma cfDNA is a possible biomarker for tocilizumab therapy in biological treatment-naïve patients. In addition, tocilizumab may suppress inflammation via the TLR9 pathway by decreasing cfDNA levels.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1514;
P4
After 24 weeks, higher remission rates were observed in men than in women for all four treatment arms, suggesting that this generalized sex difference is related to the disease itself rather than to the treatments. In contrast, a distinctly lower treatment response was seen in female patients treated with tocilizumab versus conventional treatment, suggesting a sex-effect that is specific for IL-6 blockade.
- [VIRTUAL] Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1505;
RA patients enrolled in the OBRI initiating their TOFA or TNFi (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, and Biosimilars) between 1st June 2014 (TOFA approval date in Canada) and 31st Dec 2019 were included. In this real-world data study, we found that, physician and patient reported effectiveness outcomes are similar in the TNFi and TOFA groups 6 months after treatment initiation in patients with RA.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1231;
P3
Despite not meeting the threshold for a flare, numerically higher disease activity and increases in serologic and inflammatory biomarkers were observed in PBO-randomized patients who did not experience a flare compared to those who remained on CZP. These findings confirm that patients with axSpA who achieve sustained remission benefit from continued CZP treatment, either with the full or reduced maintenance dose, over treatment withdrawal.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1229;
P3
The responses in each subgroup were consistent with those previously reported in total nr-axSpA patient group.1 ASDAS-MI response rates were lower in the CRP <5 mg/L subgroup, however, CRP is a key factor in ASDAS derivation. It is unlikely that ASDAS-MI could be achieved in patients in the CRP <5 mg/L subgroup since most of them had CRP levels < LLoQ.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non‑Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1228;
P, P3
During the double-blind period, prior to SFE entry, 75/123 PBO patients had switched to OL CZP, compared to 10/120 of CZP patients. In total, 102/120 (85.0%) and 104/123 (84.6%) SFE patients from the CZP- and PBO-randomized arms, respectively, completed the study up to Week 156.
- [VIRTUAL] Evaluation of the Safety of Vedolizumab in Combination with Other Immunosuppression Biological Therapy in Patients with Inflammatory Bowel Disease () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1223;
This retrospective study reviewing 16 cases of patients treated with vedolizumab and dual biological combination therapy demonstrates additional data regarding infection, cancer, and mortality rates. Further studies are needed to better characterize and evaluate the safety profile of vedolizumab combination therapy in IBD patients for intestinal and extra-intestinal manifestations.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1104;
P4
Table 1 shows baseline data. Adjusted CDAI remission rates at w48 were: 59.3% (for ABA), 52.3% (CZP), 51.9% (TCZ) and 39.2% (ACT), with the null hypothesis formally rejected for ACT vs ABA (adjusted difference +20.1%; adjusted p< 0.001) and ACT vs CZP (+13.1; p=0.021), but not for ACT vs TCZ (+12.7; p=0.030).
- [VIRTUAL] Predicting Treatment Change in Rheumatoid Arthritis Patients Treated with TNF Inhibitors as First-Line Biologic Agent () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_812;
Predicting treatment change in RA patients with both claims and clinically rich EHR data still remains challenging. It could be due to unmeasured factors such as prescriber’s preference or patient’s belief in the medication which may play an important role in the treatment patterns.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_736;
P3
1 TNF inhibitors such as certolizumab pegol (CZP) have been shown to improve work productivity in patients (pts) with axSpA... Achievement of optimal thresholds of clinical response in pts with axSpA after 4 years’ treatment was associated with reduced burden on paid work and household productivity, indicating the importance of targeting stringent thresholds of disease control to limit the impact of axSpA on pts’ daily lives.
- [VIRTUAL] Australian Psoriatic Arthritis (PsA) Biologic Disease-modifying Antirheumatic Drug (bDMARD) Treatment Pathways Using Sankey Diagrams and Predictive Analysis: A Combined Australian Rheumatology Association Database (ARAD) and Pharmaceutical Benefits Scheme (PBS) Analysis () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_478;
The treatment pathways for bDMARD use by PsA patients in Australia is complex with 30% switching to another bDMARD therapy after 1 year. Common reasons for switching or stopping were inefficacy and side effects.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy. (Pubmed Central) - Sep 19, 2021
The observed occurrence of major congenital malformations and miscarriages appears to be no greater than the background occurrence of those in the general population, and risks to the mother are minimal based on its known safety profile. The use of CZP for treatment of plaque psoriasis should be considered and discussed with patients considering childbearing or whom are currently pregnant or breastfeeding.
- || Clinical, Journal: Perioperative Safety of Tofacitinib in Surgical Ulcerative Colitis Patients. (Pubmed Central) - Sep 17, 2021
Mirroring the recently issued US Food and Drug Administration black box warning of an increased risk of VTE in medically treated ulcerative colitis patients taking tofacitinib, preoperative tofacitinib exposure may present an increased risk of postoperative VTE events. Consideration should be given for prolonged VTE prophylaxis on hospital discharge.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases. (Pubmed Central) - Sep 15, 2021
Consideration should be given for prolonged VTE prophylaxis on hospital discharge. The current data are reassuring for low mAb drug transfer to breastmilk, but further studies are needed, including of longer-term effects on infant immunity and childhood development.
- || Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
“Median stop time points were gestational age (GA) 37.0 weeks for certolizumab pegol, GA 25.0 weeks for etanercept,” could this be the reason? (Twitter) - Sep 13, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB
Interesting, but likely not practice changing for me unless approval is given for use in pregnancy like with cimzia. (Twitter) - Sep 13, 2021
- |||| Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
Reimbursement: Potentially practice changing— currently recommend certolizumab for pregnant women (if insurances approve) but data suggests less placental cross over with etanercept. thoughts? @BolekBerqui @LCalabreseDO @RheumNow @DrBhana @Linherski @EBRheum #rheumatology #rheumatoidarthritis (Twitter) - Sep 13, 2021
- | Retrospective data, Journal, Real-world evidence: Real world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study from Southern Italy in the years 2010-2014. (Pubmed Central) - Sep 12, 2021
Prevalence of use and costs of biological drugs for PsO/PsA substantially increased in recent years in a large population of Southern Italy. Larger uptake of lowest cost biological drugs, and biosimilars whenever available, may help access to the most innovative drugs.
- Temporal Trends of Utilization of Biologics as First-Line Therapy in the Management of Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Study (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2902;
We identified 182,310 (0.30%) patients with CD and 148,300 (0.25%) patients with UC, of which 20,790 (11.4%) and 10,400 (7.0%) patients received biologics as a first line therapy, respectively. The utilization of biologics as first line therapy in the management of CD progressively increased from 4.9% in 2010 to 13.7% in 2020.
- Treatment Patterns Among Crohn’s Disease Patients Initiating Biologics: A Two-Year Pooled Analysis of Three United States Claims Databases (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2863;
Persistence, over two years, was numerically highest for UST patients followed by IFX, VDZ, and ADA and trends were similar across bio-naïve and bio-experienced CD patients (Figure). Over 2 years of follow-up, 50% dose escalation and 50% dose reduction were numerically highest among ADA patients followed by UST and VDZ; Bio-naïve and bio-experienced patients followed a similar trend except for VDZ where bio-experienced patients had a slightly higher rate of dose escalation than bio-naïve patients (Table 1).
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Cimzia (certolizumab pegol) / Astellas, UCB
Managing Crohn’s Disease With a Vegan Diet (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2448;
In 2010, patient underwent a laparoscopic left hemicolectomy with ascending colon to rectal anastomosis after failing cyclosporine for fulminant colitis involving the rectum, sigmoid, descending colon, splenic flexure, distal transverse colon...She was recommended to start ustekinumab, but opted against further medication in favor of lifestyle modification...Gastroenterol. 2011; 563–573Figure: Top row: photographs from colonoscopy in 2019 of A) Terminal ileum with ileo-ileal anastomosis, ulceration, moderate stenosis B) Colorectal anastomosis with inflammation and ulceration C) Severe proctitis Bottom row: photographs from colonoscopy in 2020 of D) Terminal ileum with focal ulceration E) Colorectal anastomosis with healthy-appearing mucosa F) Rectum with marked improvement
- Cimzia (certolizumab pegol) / Astellas, UCB
Pharmacovigilance Data on Pregnancy Outcomes in Women With Crohn’s Disease Exposed to Certolizumab Pegol (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_2208;
Rates of live birth and pregnancy loss were 88.4% and 10.5%, respectively, in the total population (Table). In the multivariate analysis, CD and NSAID use were significantly associated with decreased live births and increased pregnancy loss (Figure).
- Let’s Get You Comfortable in Your Own Skin: Response of Metastatic Crohn’s Disease to Ustekinumab (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_1988;
After roughly one month of CsA, she transitioned to oral tacrolimus...(C) Gluteal cleft lesion and (D) perineal lesion prior to UST infusion. (E) Gluteal cleft lesion and (F) perineal lesion 2 months after UST induction infusion.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Delay in Insurance Approval of Biologic Therapy Dose Escalation Is Associated With Increased Disease Activity in Patients With Inflammatory Bowel Disease (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_1916;
Demographics and dosing regimens are shown in Table 1. Mean time from decision to escalate dose to insurance approval was 11.1 days (SD = 20.9).
- Efficacy and Safety of Biological Therapy in Microscopic Colitis: Systematic Review and Meta-Analysis (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_1482;
Most studies were case series. 11 articles were included in the meta-analyses (Table 1).
- Sequencing of Anti-TNF Agents and Vedolizumab in the Treatment of Crohn’s Disease (CD) (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_1116;
Among the 1L VDZ pts, only 35 switched to anti-TNF as 2L biologic treatment (VDZ to anti-TNF). Among the 1L anti-TNF pts, 265 switched to VDZ as 2L biologic therapy (anti-TNF to VDZ).
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Non-Adherence to Self-injectable Biologic Therapy in IBD Increases ED Visits and Hospitalizations (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_483;
The median follow-up time was 903 days (range 187, 3900). Median MPR was similar across centers (Center 1: 0.94 [IQR 0.62, 1], Center 2: 0.99 [IQR 0.69, 1], and Center 3: 0.92 [IQR 0.77, 1]), p = NS.
- | Cimzia (certolizumab pegol) / Astellas, UCB
تداخلات اتانول/ تغذیه/ ترکیبات گیاهی: گیاهان دارویی: Echinacea اثرات درمانی Certolizumab را کاهش می دهد؛ از استفاده همزمان اجتناب کنیدامید است که این دارو زود تر موجود شود@merck (Twitter) - Sep 7, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients with Rheumatoid Arthritis. (Pubmed Central) - Sep 4, 2021
Receiver operating characteristic (ROC) analysis showed that CZP concentrations ≥28.0 μg/mL at Week 12, and ≥17.6 μg/mL at Week 24, were associated with a greater likelihood of achieving LDA/remission outcomes. Although confirmatory studies are warranted to define the optimal CZP therapeutic range at Weeks 12 and 24, these data indicate that CZP concentrations may be associated with improvement of disease activity.
- | Journal: Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors. (Pubmed Central) - Sep 3, 2021
Hernandez has served on Pfizer's scientific advisory board. The other authors have nothing to disclose.
- || Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Review, Journal: Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. (Pubmed Central) - Sep 3, 2021
Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Aclaris, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Ortho, Pfizer, Rapt, Regeneron, Sandoz, Sanofi Genzyme, Sun Pharma, and UCB Pharma and as a paid speaker for AbbVie. Burge, Zhu, Malatestinic, Brnabic, Guo, and Janardhanan are employees and shareholder of Eli Lilly and Company.